PHAT — Phathom Pharmaceuticals, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1783183 ·
Last close
$5.50
Market Cap
$447.10M
52W High
$18.31
52W Low
$5.01
ADV30
1,686,848
Next earnings
2026-10-29

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 84,722,000 66,355,000 -85,000 -13,897,000 345,020,000 184,558,000 692,659,000
Jun 2026 74,274,000 59,178,000 -3,965,000 -17,582,000 327,075,000 182,478,000 671,348,000
Mar 2026 58,301,000 46,305,000 -15,477,000 -30,369,000 305,120,000 180,904,000 642,075,000
Dec 2025 57,584,000 49,936,000 -5,928,000 -21,148,000 259,149,000 129,972,000 697,318,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-20,739,000
Investing CF
$-302,000
Financing CF
$70,445,000
CapEx
$-302,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.03
As of
2026-11-01

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,546,106,000
Inventory
$7,632,000
Receivables
$107,602,000
ST Investments
—
EBIT TTM
$-20,290,000
Pretax Income TTM
$-82,996,000
Interest Exp TTM
$62,706,000
Analysts
10

Yahoo Snapshot (yfinance, live)

Total Revenue
$274,880,992
EBITDA
$-24,984,000
Free Cash Flow
$-12,944,250
Enterprise Value
$837,505,216
Total Cash
$184,558,000
Total Debt
$555,449,984
Shares Out
81,291,520
Trailing EPS
$-1.26
Book Value
$-4.30
ROE
—
ROA
-5.4%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 175,110,000 -159,986,000 -221,247,000 259,149,000 697,318,000 -438,169,000 -166,775,000
Dec 2024 55,252,000 -277,467,000 -334,326,000 378,318,000 631,898,000 -253,580,000 -266,770,000
Dec 2023 682,000 -167,312,000 -201,592,000 413,842,000 486,601,000 -72,759,000 -137,580,000
Dec 2022 0 -172,440,000 -197,723,000 164,810,000 239,624,000 -74,814,000 -146,530,000

TTM Snapshot

Revenues TTM
$239,663,000
NetIncome TTM
$-99,072,000
OpCashFlow TTM
—
Assets (Latest)
$327,075,000
Forward EPS
$1.08

Max Pain — expiry 2028-01-21

max pain strike: $7.50 · spot: $5.30 · call oi: 8,050 · put oi: 187
Expected Move to 2028-01-21: ±$7.43 (140.19%) — implied range $-2.13 – $12.73 · ATM straddle on $5.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ARVN ARVINAS, INC. $446.61M $6.82 —
EOLS Evolus, Inc. $442.80M $6.69 —
INDP Indaptus Therapeutics, Inc. $442.36M $3.32 —
DMAC DiaMedica Therapeutics Inc. $452.16M $8.38 —
EPRX EUPRAXIA PHARMACEUTICALS INC. $437.41M $6.62 —

News headlines (Yahoo Finance, 1h cache)

Phathom Pharmaceuticals Marks GERD Awareness Week 2026 by Urging Americans to Take Frequent Heartburn Seriously
2026-11-19 13:00 · Yahoo
Phathom: 3 Key Takeaways for Long-Term Investors
2026-11-18 21:05 · Yahoo
What Comes Next For Phathom Pharmaceuticals After A 65% Slide
2026-11-18 19:06 · Yahoo
Implied Volatility Surging for Phathom Pharmaceuticals Stock Options
2026-11-06 13:00 · Yahoo
What Phathom Pharmaceuticals Bears Spotted Before A 63% Slide
2026-11-04 13:12 · Yahoo
Phathom Pharmaceuticals to Participate in November Investor Conferences
2026-11-04 13:00 · Yahoo
Phathom Pharmaceuticals Announces Eligible Commercially Insured Patients May Now Pay as Little as $0 for VOQUEZNA® (vonoprazan) Tablets Exclusively at BlinkRx
2026-11-03 13:00 · Yahoo
What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call
2026-10-29 21:14 · Yahoo
Phathom Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
2026-10-29 21:01 · Yahoo
Phathom (PHAT) Q3 2026 Earnings Call Transcript
2026-10-29 18:43 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.